Lantern Pharma (LTRN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
19 Oct, 2026Executive summary
Virtual annual meeting scheduled for Dec. 1, 2026; holders of record on Oct. 5, 2026 may vote, with 14,935,576 common shares outstanding and one vote per share.
Board recommends FOR all seven proposals, including six director nominees, capital and equity-plan amendments, warrant-share issuance, auditor ratification, say-on-pay, and annual say-on-pay votes.
Voting matters and shareholder proposals
Proposal 1 seeks election of Donald Jeff Keyser, Panna Sharma, Vijay Chandru, Maria Maccecchini, Lee T. Schalop, and David S. Silberstein for one-year terms; plurality vote elects the six nominees.
Proposal 2 would double authorized common shares from 25 million to 50 million; only 281,597 shares were unissued and unreserved as of Oct. 5, 2026.
Proposal 3 seeks 250,000 additional Equity Incentive Plan shares, bringing the plan reserve to 2,114,680; 425,633 shares would be available for new awards if approved.
Proposal 4 seeks approval for up to 3,669,725 warrant shares at $1.09 each; full exercise could yield ~$4.0 million for working capital and general purposes while diluting existing holders.
Proposals 5–7 seek 2026 EisnerAmper ratification, advisory executive-pay approval, and a preferred say-on-pay frequency; the Board recommends FOR and one year, respectively.
Board of directors and corporate governance
Board has six members, five independent; Donald Jeff Keyser is chair and Panna Sharma is CEO and president, with no lead director.
In 2025, the Board met six times and acted five times by unanimous written consent; all directors attended at least 75% of Board and committee meetings.
Independent Audit, Compensation, and Nominating and Corporate Governance committees oversee their respective mandates; committee chairs are Keyser, Maccecchini, and Chandru.
Proxy access permits a holder or group of up to 10 with at least 3% ownership for three years to nominate up to the greater of two directors or 20% of the Board, subject to bylaw requirements.
Latest events from Lantern Pharma
- Clinical catalysts and an AI spinout plan anchor the next phase of development.LTRN
The ThinkEquity Conference - Seven proposals seek capital flexibility, more plan shares and warrant issuance approval.LTRN
Proxy filing - Open Medicine expands its AI drug-development platform amid adoption and financing plans.LTRN
Investor update - OMAI spun out, clinical pipeline advanced, and Q2 operating loss fell 25% year-over-year.LTRN
Q2 2026 - LP-184 shows strong safety, durable responses, and precision potential in DNA repair-deficient tumors.LTRN
Status Update - AI-driven oncology pipeline delivers strong clinical results and expands global trial reach.LTRN
Corporate presentation - AI-driven cancer drug developer registers 2.24M shares for resale; funding needs remain urgent.LTRN
Registration filing - Q1 2026 net loss fell 27% to $3.33 million, with liquidity sufficient through mid-Q1 2027.LTRN
Q1 2026 - AI-driven withZeta.ai revolutionizes rare cancer drug discovery with real-time, collaborative tools.LTRN
Investor update